Study Summary
This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.
Want to learn more about this trial?
Request More InfoInterventions
KL003 Cell Injection Drug ProductDRUG
Administered by intravenous infusion after myeloablative conditioning with busulfan.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai | Shanghai Municipality | China |
| Institute of Hematology & Blood Diseases Hospital | Tianjin | Tianjin Municipality | China |